Assessing the prevalence and patterns of COVID-19 vaccine side effects among Syrian adults: A cross-sectional study.

AstraZeneca COVID-19 Fever Lethargy Side effect Sleepiness Sputnik Light Vaccine

Journal

Preventive medicine reports
ISSN: 2211-3355
Titre abrégé: Prev Med Rep
Pays: United States
ID NLM: 101643766

Informations de publication

Date de publication:
Jan 2024
Historique:
received: 22 06 2023
revised: 24 11 2023
accepted: 11 12 2023
medline: 29 1 2024
pubmed: 29 1 2024
entrez: 29 1 2024
Statut: epublish

Résumé

This study aimed to assess the prevalence and patterns of COVID-19 vaccine side effects among Syrian adults, with a focus on the AstraZeneca and Sputnik Light vaccines, in light of the low vaccination rate in Syria (below 18%) attributed to fear of side effects. A cross-sectional study was conducted between January and May 2022, using probability-based and convenient sampling strategies. Data was collected through online, paper, and face-to-face questionnaires that included demographic and vaccine-related questions. Out of 3,766 participants, the majority were female (56.7 %) and aged 18-24 years (53.3 %). Most participants had a university-level qualification (71.2 %) and were related to the medical sector (53.2 %). A significant proportion (47.0 %) received AstraZeneca, Sputnik Light (22.1 %) and Sinopharm (14.7 %). Common side effects included sleepiness and lethargy (50.0 %), fever and chills (45.0 %), and pain/swelling at the injection site (35.9 %). Multivariate logistic regression analysis revealed that male (OR: 0.57, CI: 0.48-0.68) and participants aged 45-65 years (OR: 0.53, CI: 0.40-0.70) were less likely to experience side effects. Participants who believed COVID-19 posed a high threat to their personal life had higher odds of side effects (OR: 1.74, CI: 1.22-2.46). Vaccine type was also associated with side effects, with Sputnik Light (OR: 2.52, CI: 1.85-3.46) and AstraZeneca (OR: 1.61, CI: 1.26-2.05) having increased odds. Our study found that COVID-19 vaccines are well tolerated among the Syrian population, with short-term side effects that typically resolve within three days. These findings are expected to bolster vaccination rates through enhanced public confidence and acceptance.

Identifiants

pubmed: 38282667
doi: 10.1016/j.pmedr.2023.102558
pii: S2211-3355(23)00449-7
pmc: PMC10810828
doi:

Types de publication

Journal Article

Langues

eng

Pagination

102558

Informations de copyright

© 2023 The Authors.

Déclaration de conflit d'intérêts

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Mohamad Klib (M)

Faculty of Medicine, Damascus University, Damascus, Syria.

Osama Alazki (O)

Faculty of Medicine, Tishreen University, Latakia, Syria.

Ayman Issa Nabhan (A)

Faculty of Medicine, Al Andalus University for Medical Sciences, Tartus, Syria.

Aml M Brakat (AM)

Faculty of Medicine, Zagazig University, Ash Sharqia Governorate ,Egypt.

Bana Zuhair Alafandi (B)

Faculty of Medicine, University of Aleppo, Aleppo, Syria.

Fatima Abdulmoain Idres (F)

Faculty of Medicine, AL-Baath University, Homs, Syria.

Ruba Almenchaf (R)

Faculty of Medicine, AL-Baath University, Homs, Syria.

Farah Albakkar (F)

Faculty of Medicine, University of Aleppo, Aleppo, Syria.

Munir Ghandour (M)

Faculty of Medicine, Damascus University, Damascus, Syria.

Jaafar Zahlout (J)

Faculty of Medicine, Tishreen University, Latakia, Syria.

Somayya Tabsho (S)

Faculty of Medicine, University of Aleppo, Aleppo, Syria.

Samar Mouazen (S)

Faculty of Medicine, Damascus University, Damascus, Syria.

Classifications MeSH